Motor and mental aspects of extrapyramidal syndromes

Daniel Casey

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Neuroleptic-induced extrapyramidal syndromes (EPS) are major limitations to effective antipsychotic therapy. There are both motor (objective) and mental (subjective) components to EPS, which must be considered in the evaluation and differential diagnosis of treatment-related adverse events. In addition to causing motor impairment, these syndromes can also produce irritability, anxiousness and secondary negative symptoms of slow thinking and emotional blunting. The EPS of akathisia, dystonia, and parkinsonism have unique characteristics that are influenced by patient, drug and temporal aspects. With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.

Original languageEnglish (US)
Pages (from-to)105-114
Number of pages10
JournalInternational Clinical Psychopharmacology
Volume10
StatePublished - 1995

Fingerprint

Antipsychotic Agents
Psychomotor Agitation
Dystonia
Parkinsonian Disorders
Differential Diagnosis
Rehabilitation
Therapeutics
Pharmaceutical Preparations
Thinking

Keywords

  • Dopamine antagonists
  • Extrapyramidal syndromes
  • Neuroleptics
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Motor and mental aspects of extrapyramidal syndromes. / Casey, Daniel.

In: International Clinical Psychopharmacology, Vol. 10, 1995, p. 105-114.

Research output: Contribution to journalArticle

@article{4fec8bd448f344e1a5ea320788ec1c8d,
title = "Motor and mental aspects of extrapyramidal syndromes",
abstract = "Neuroleptic-induced extrapyramidal syndromes (EPS) are major limitations to effective antipsychotic therapy. There are both motor (objective) and mental (subjective) components to EPS, which must be considered in the evaluation and differential diagnosis of treatment-related adverse events. In addition to causing motor impairment, these syndromes can also produce irritability, anxiousness and secondary negative symptoms of slow thinking and emotional blunting. The EPS of akathisia, dystonia, and parkinsonism have unique characteristics that are influenced by patient, drug and temporal aspects. With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.",
keywords = "Dopamine antagonists, Extrapyramidal syndromes, Neuroleptics, Schizophrenia",
author = "Daniel Casey",
year = "1995",
language = "English (US)",
volume = "10",
pages = "105--114",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Motor and mental aspects of extrapyramidal syndromes

AU - Casey, Daniel

PY - 1995

Y1 - 1995

N2 - Neuroleptic-induced extrapyramidal syndromes (EPS) are major limitations to effective antipsychotic therapy. There are both motor (objective) and mental (subjective) components to EPS, which must be considered in the evaluation and differential diagnosis of treatment-related adverse events. In addition to causing motor impairment, these syndromes can also produce irritability, anxiousness and secondary negative symptoms of slow thinking and emotional blunting. The EPS of akathisia, dystonia, and parkinsonism have unique characteristics that are influenced by patient, drug and temporal aspects. With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.

AB - Neuroleptic-induced extrapyramidal syndromes (EPS) are major limitations to effective antipsychotic therapy. There are both motor (objective) and mental (subjective) components to EPS, which must be considered in the evaluation and differential diagnosis of treatment-related adverse events. In addition to causing motor impairment, these syndromes can also produce irritability, anxiousness and secondary negative symptoms of slow thinking and emotional blunting. The EPS of akathisia, dystonia, and parkinsonism have unique characteristics that are influenced by patient, drug and temporal aspects. With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.

KW - Dopamine antagonists

KW - Extrapyramidal syndromes

KW - Neuroleptics

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0029584169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029584169&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 105

EP - 114

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

ER -